Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid Donanemab (Anti-Amyloid Beta)
For research use only. Not for use in humans.

Donanemab (Anti-Amyloid Beta)

Synonyms: LY3002813

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.

Donanemab (Anti-Amyloid Beta)

Quality Control

Batch: Purity: 99% Protein concentration: 9.125mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Beta Amyloid Others
DAPT 404 Notch
RO4929097 (RG-4733) 126 γ secretase,Notch
Semagacestat (LY450139) 22 Notch
MK-0752 23
Avagacestat (BMS-708163) 22
LY2811376 19 BACE1
CRANAD-2 0
Hoechst 34580 2
Frentizole 0
Simufilam 1
Ginsenoside Rg1 7 NF-κB
Ginsenoside Re 2 NF-κB,JNK
Tabersonine hydrochloride 2
EUK 134 8
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.
References

Product Details

CAS No. 1931944-80-7
Molecular Weight 145.36
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06996730 RECRUITING Drug: Donanemab|Drug: RG6289|Drug: Donanemab placebo|Drug: R Autosomal Dominant Alzheimers Disease; Early Onset Alzheimer Disease; Alzheimers Disease Banner Health 2026-07-08 PHASE2; PHASE3
NCT07571161 RECRUITING Drug: Donanemab|Drug: Placebo Alzheimer Disease Eli Lilly and Company 2026-04-30 PHASE3
NCT07602582 RECRUITING Drug: Donanemab|Drug: Placebo Alzheimer Disease; Dementia; Plaque, Amyloid Eli Lilly and Company 2026-05-22 PHASE3
NCT06911944 NOT_YET_RECRUITING Drug: Donanemab|Drug: Placebo Down Syndrome (DS); Down Syndrome (Trisomy 21); Alzheimer Disease; Amyloid Beta Protein Michael Rafii, MD, PhD 2026-08-01 PHASE4
NCT07167966 ENROLLING_BY_INVITATION Drug: AADvac1|Drug: Donanemab Preclinical Alzheimer's Disease; Prodromal Alzheimer's Disease; Alzheimer Disease Paul S. Aisen 2026-11-03 PHASE2
NCT07589595 RECRUITING Drug: Donanemab|Drug: Placebo Cognitive Dysfunction; Lewy Body Disease; Synucleinopathies; Amyloid Eli Lilly and Company 2026-05-20 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.